Table 2.
Survival data selected for analysis
| Author | Pretherapeutic stage | Group (Case Number) | Two‐year OS | Five‐year OS | Two‐year DFS | Five‐year DFS |
|---|---|---|---|---|---|---|
| Castoro et al.14 | I–IV†† | A (39) | 72.6% | 50% | 62.3% | 55.5% |
| B (38) | 72.6% | 57% | 40.0% | 34.6% | ||
| Piessen et al.15 | II–III | A (118) | 83.7% | 68.0% | 74.0% | 57.4% |
| B (59) | 58.6% | 40.5% | 52.6% | 33.4% | ||
| Chao et al.16 | II–IV†† | A (71) | — | 41% | — | 44% |
| B (79) | — | 39% | — | 45% | ||
| Jeong et al.17 | II–IV† | A (73) | 60.3% | — | 72.4% | — |
| B (81) | 37% | — | 35.6% | — |
†
Patients with distant metastasis at diagnosis were excluded, while those with stage IV disease resulting from nodal involvement were included. Patients were staged according to the 6th Amercian Joint Committee for Cancer Tumor Node Metastasis classification.
A, CRT + Surgery; B, non‐surgical approach; DFS, disease‐free survival; OS, overall survival.